EP3837280A1 - Hémoglobines recombinantes et leurs procédés de préparation et d'utilisation - Google Patents

Hémoglobines recombinantes et leurs procédés de préparation et d'utilisation

Info

Publication number
EP3837280A1
EP3837280A1 EP20747899.1A EP20747899A EP3837280A1 EP 3837280 A1 EP3837280 A1 EP 3837280A1 EP 20747899 A EP20747899 A EP 20747899A EP 3837280 A1 EP3837280 A1 EP 3837280A1
Authority
EP
European Patent Office
Prior art keywords
seq
sequence
amino acid
polynucleotide encoding
recombinant hemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20747899.1A
Other languages
German (de)
English (en)
Other versions
EP3837280A4 (fr
Inventor
Sui Yi Kwok
Norman Fung Man Wai
Shan Yu
Terence Shau Yin WAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cheer Global Ltd
Original Assignee
Cheer Global Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheer Global Ltd filed Critical Cheer Global Ltd
Publication of EP3837280A1 publication Critical patent/EP3837280A1/fr
Publication of EP3837280A4 publication Critical patent/EP3837280A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Definitions

  • the present disclosure generally relates to recombinant hemoglobins and methods preparation, purification, and use thereof.
  • the present disclosure further relates to pharmaceutical compositions comprising the recombinant hemoglobins and methods of using the recombinant hemoglobin-based pharmaceutical composition to treat oxygen deficiency related diseases, such stroke, hemorrhagic shock, peripheral arterial disease (PAD) and acute mountain sickness (AMS) , and other diseases or conditions, such as cancer and Parkinson’s disease (PD) .
  • oxygen deficiency related diseases such stroke, hemorrhagic shock, peripheral arterial disease (PAD) and acute mountain sickness (AMS)
  • AMS acute mountain sickness
  • PD Parkinson’s disease
  • Hemoglobin is an oxygen-carrying protein enriched in red blood cells (erythrocytes) that delivers oxygen to body tissues via blood flow through the circulatory system.
  • the oxygen-carrying protein comprises four associated polypeptide chains (two alpha chains and two beta chains) , and bears a group known as heme whose iron atom temporarily binds to oxygen in the lungs and releases it throughout the body.
  • Hemoglobin can also bind carbon monoxide (CO) to form (carbonmonoxy) hemoglobin (HbCO) , which can reduce the total amount of Hb that is available to deliver oxygen to the body.
  • CO carbon monoxide
  • HbCO carbon monoxide
  • Hypoxia is common in cancers and can lead to ionizing radiation and chemotherapy resistance by depriving tumor cells of the oxygen essential for the cytotoxic activities of these agents. Hypoxia may also reduce tumor sensitivity to radiation therapy and chemotherapy through one or more indirect mechanisms that include proteomic and genomic changes.
  • Hemoglobin extracted from red blood cells has been used as a blood substitute for oxygen delivery to hypoxic tissues.
  • the use of unmodified cell-free Hb purified from red blood cells can suffer from several limitations, such as contamination, supply limitations, an increase in oxygen affinity due to loss of the cofactor 2, 3-disphosphoglycerate (2, 3-DPG) , and dissociation of Hb tetramers into ⁇ dimers, which are cleared by renal filtration and can cause long-term kidney damage.
  • Existing methods for preparing recombinant hemoglobins generally include a heat treatment step to remove impurities, such as PPIX.
  • a heat treatment step to remove impurities, such as PPIX.
  • the incorporation of a heat treatment step into the preparation method can increase cost and reduce yield of the protein product.
  • CO is required for the recombinant hemoglobins.
  • a CO removal step is usually required for existing preparation methods, which also makes the existing methods costly and time-consuming.
  • the present disclosure generally relates to recombinant hemoglobins and methods of use and preparation thereof.
  • the recombinant hemoglobins described herein can have improved oxygen-carrying capacity.
  • the disclosed recombinant hemoglobins are useful for treating diseases, such as cancer, stroke, hemorrhagic shock, acute mountain sickness (AMS) , peripheral arterial disease (PAD) and Parkinson’s disease (PD) .
  • diseases such as cancer, stroke, hemorrhagic shock, acute mountain sickness (AMS) , peripheral arterial disease (PAD) and Parkinson’s disease (PD) .
  • the present disclosure also generally relates to methods of preparing the recombinant hemoglobins described herein.
  • the recombinant hemoglobins prepared using the methods described herein can have reduced amounts of PPIX, little or no HbCO, and an optimal heme/protein ratio and tetramer/dimer distribution.
  • a recombinant hemoglobin comprising a di-alpha chain and two beta chains, wherein the di-alpha chain comprises a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine.
  • the di-alpha chain comprises a polypeptide sequence having at least 99.29%sequence homology with SEQ ID NO: 1.
  • the di-alpha chain comprises a polypeptide having at least 99.64%sequence homology with SEQ ID NO: 1.
  • the di-alpha chain is a polypeptide sequence having SEQ ID NO: 1.
  • each of the two beta chains comprises a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 2, wherein the amino acid at position 1 must be methionine.
  • each of the two beta chains is a polypeptide sequence having SEQ ID NO: 2.
  • each of the two beta chains comprises a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 3, wherein the amino acid at position 1 must be methionine, the amino acid at position 82 must be aspartic acid, and the amino acid at position 108 must be lysine.
  • each of the two beta chains comprises a polypeptide sequence having at least 98.63%sequence homology with SEQ ID NO: 3.
  • each of the two beta chains comprises a polypeptide sequence having at least 99.31%sequence homology with SEQ ID NO: 3.
  • each of the two beta chains comprises a polypeptide sequence of SEQ ID NO: 3.
  • a pharmaceutical composition comprising the above-mentioned recombinant hemoglobin and at least one pharmaceutically acceptable carrier.
  • a method of treating an oxygen deficiency related disease in a subject in need thereof comprising the step of administering a therapeutically effective amount of the pharmaceutical composition to the subject.
  • the oxygen deficiency related disease comprises cancer, stroke, hemorrhagic shock, acute mountain sickness (AMS) , peripheral arterial disease (PAD) or Parkinson’s disease (PD) .
  • a method of producing the recombinant hemoglobin comprising the steps of:
  • the polynucleotide encoding the di-alpha chain and the polynucleotide encoding the beta chain comprise a polynucleotide sequence of SEQ ID NO: 4 and a polynucleotide sequence of SEQ ID NO: 5, respectively.
  • the polynucleotide encoding the di-alpha chain and the polynucleotide encoding the beta chain comprises a polynucleotide sequence of SEQ ID NO: 4 and a polynucleotide sequence of SEQ ID NO: 6, respectively.
  • the host cell is selected from the group consisting of JM109 E. coli bacterial strain with lambda DE3, BL21-AI E. coli bacterial strain without lambda DE3, and SHuffle E. coli bacterial strain without lambda DE3.
  • the host cell further comprises a polynucleotide encoding HemH.
  • the host cell further comprises a polynucleotide encoding a Heme-transporter.
  • the method further comprises the steps of:
  • a system for producing the recombinant hemoglobin of the first aspect of the present disclosure comprising: an Escherichia coli or non-Escherichia coli host cell comprising: a polynucleotide encoding HemH; a polynucleotide encoding a Heme-transporter; a polynucleotide encoding a di-alpha chain; and a polynucleotide encoding a beta chain, wherein the di-alpha chain comprises a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine; and the beta chain
  • FIG. 1 shows the polypeptide sequences for di-alpha chain SEQ ID NO: 1 and SEQ ID NO: 11 and beta chain SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 12 according to certain embodiments described herein.
  • FIG. 2A shows the plasmid maps, where pACYCDuet-CT is the vector carrying the ChuA gene and the gene for expressing TonB, and pET-HemHm1-TB is a general plasmid that carries the sequence for expressing HemH mutant and TB, where TB can be the sequence for expressing TBN, TBM1, or TBM9.
  • FIG. 2B shows the SDS-PAGE analysis of TBN, TBM1 and TBM9 expression in different cell strains by the plasmid in FIG. 2A, wherein #83 is the result for TBM1 expressed in SHuffle E. coli bacterial strain without lambda DE3, #84 is the result for TBM9 expressed in SHuffle E. coli bacterial strain without lambda DE3, #85 is the result for TBM1 expressed in JM109 T7CT CRISPR/Cas9 E. coli bacterial strain without lambda DE3, #86 is the result for TBM9 expressed in JM109 T7CT CRISPR/Cas9 E. coli bacterial strain without lambda DE3, and #43 is the result for TBN expressed in JM109 E. coli bacterial strain with lambda DE3.
  • FIG. 2C shows the SDS-PAGE analysis of TBN, TBM1 and TBM9 expression in different cell strains by the plasmid in FIG. 2A, wherein #83 is the result for TBM1 expressed in SHuffle E. coli bacterial strain without lambda DE3, #84 is the result for TBM9 expressed in SHuffle E. coli bacterial strain without lambda DE3, #85 is the result for TBM1 expressed in JM109 T7CT CRISPR/Cas9 E. coli bacterial strain without lambda DE3, #86 is the result for TBM9 expressed in JM109 T7CT CRISPR/Cas9 E. coli bacterial strain without lambda DE3, and #43 is the result for TBN expressed in JM109 E. coli bacterial strain with lambda DE3.
  • FIG. 3A shows the illustration of the liver oxygen level measurement in a mouse model.
  • FIG. 3B shows the change of the liver oxygen level of the mouse model over 180 min after the administration of TBN, TBM1, TBM9, YQ (bovine fumaryl crosslinked Hb) , and RA-buffer as a control.
  • FIG. 4A shows a ultra-high performance liquid chromatography (UPLC) chromatogram showing the heme and PPIX levels of purified protein expressed using the previous plasmid comprising the nucleotide sequences of TBN (FIG. 4A) .
  • UPLC ultra-high performance liquid chromatography
  • FIG. 4B shows a UPLC chromatogram showing the heme and PPIX level of purified protein expressed using the new improved plasmid comprising nucleotide sequences of HemH mutant, Heme transporter system (ChuA and TonB) , and TBN (FIG. 4B) .
  • FIG. 5A shows the oxygen equilibrium curve for different recombinant human hemoglobins (TBN, TBM1, and TBM9) according to certain embodiments described herein.
  • FIG. 5B shows a table of the p50 value of different recombinant human hemoglobins (TBN, TBM1, and TBM9) with and without 2, 3-DPG according to certain embodiments described herein.
  • FIG. 5C shows an oxygen equilibrium curve of TBM1 with and without 2,3-DPG according to certain embodiments described herein.
  • FIG. 6 shows a purification flow-chart according to certain embodiments described herein.
  • FIG. 7 shows the HemH mutant polynucleotide SEQ ID NO: 8 (top) and HemH mutant protein SEQ ID NO: 13 (bottom) according to certain embodiments described herein.
  • FIG. 8 shows the ChuA polynucleotide SEQ ID NO: 9 (top) and ChuA protein SEQ ID NO: 14 (bottom) according to certain embodiments described herein.
  • FIG. 9 shows the TonB polynucleotide SEQ ID NO: 10 (top) and TonB protein SEQ ID NO: 15 (bottom) according to certain embodiments described herein.
  • FIG. 10 shows a graph (top) and table (bottom) showing the azide-induced oxidation rates (k az ) values of TBN, TBM1, and TBM9.
  • FIG. 11 shows MTT assay results for recombinant human hemoglobins TBM1 and TBM9 inhibiting 4T1 breast cancer cell proliferation in vitro.
  • FIG. 12A show the recombinant human hemoglobins (TBM1) suppressing 4T1 breast cancer cell growth in vivo.
  • FIG. 12B shows a bar graph showing the recombinant human hemoglobins (TBM1) suppressing 4T1 breast cancer cell growth in vivo.
  • FIG. 13 shows the results of a murine PAD model results using saline and recombinant human hemoglobin (TBM1) .
  • FIG. 14 shows body weight results after treating with recombinant human hemoglobin (TBM1) in Balb/c and ICR mice.
  • the present disclosure relates to recombinant hemoglobins having high oxygen carrying capacity.
  • the recombinant hemoglobins described herein comprise a di-alpha chain and two beta chains.
  • recombinant hemoglobin (s) indicates a hemoglobin molecule and/or its variant with a molecular size of at least approximately 65 kDa and is synthesized by any standard molecular biology techniques rather than being isolated or purified from any animal or human source.
  • protein or “polypeptide” as used herein indicates an organic polymer composed of two or more amino acid monomers and/or analogs thereof.
  • polypeptide includes amino acid polymers of any length including full length proteins and peptides, as well as analogs and fragments thereof. A polypeptide of three or more amino acids is also called an oligopeptide.
  • amino acid amino acid monomer
  • amino acid residue refers to any of the twenty naturally occurring amino acids including synthetic amino acids with unnatural side chains and including both D and L optical isomers.
  • amino acid analog and “analog” that are used interchangeably refer to an amino acid in which one or more individual atoms have been replaced, either with a different atom, isotope, or with a different functional group but is otherwise identical to its natural amino acid analog and have similar chemical and/or physical properties to its natural amino acid analog.
  • variant refers to a polypeptide or polynucleotide sequence differing from a reference polypeptide or polynucleotide sequence, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the reference polypeptide or polynucleotide sequence.
  • a variant can, for example, comprise the amino acid sequence of the parent polypeptide sequence with at least one conservative amino acid substitution.
  • the variant can comprise the amino acid sequence of the parent polypeptide sequence with at least one non-conservative amino acid substitution.
  • the non-conservative amino acid substitution may enhance the biological activity of the variant, such that the biological activity of the variant is increased as compared to the parent polypeptide.
  • amino acid modification indicates amino acid insertion, substitution, or deletion, etc.
  • Amino acid substitutions of the described polypeptides can be conservative amino acid substitutions.
  • Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and/or chemical properties is exchanged for another amino acid that has the same or similar chemical or physical properties.
  • the conservative amino acid substitution can be an acidic/negatively charged polar amino acid substituted for another acidic/negatively charged polar amino acid (e.g., Asp or Glu) , an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Cys, Val, etc. ) , a basic/positively charged polar amino acid substituted for another basic/positively charged polar amino acid (e.g. Lys, His, Arg, etc.
  • an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Cys, Val, etc.
  • a basic/positively charged polar amino acid substituted for another basic/positively charged polar amino acid e.g. Lys, His, Arg, etc.
  • an uncharged amino acid with a polar side chain substituted for another uncharged amino acid with a polar side chain e.g., Asn, Gln, Ser, Thr, Tyr, etc.
  • an amino acid with a beta-branched side-chain substituted for another amino acid with a beta-branched side-chain e.g., Ile, Thr, and Val
  • an amino acid with an aromatic side-chain substituted for another amino acid with an aromatic side chain e.g., His, Phe, Trp, and Tyr
  • nucleotide modifications refers to nucleotide insertion, substitution, deletion, etc.
  • percentage sequence homology when used in reference to a polypeptide or polynucleotide sequence, refers to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
  • the percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions for the longer sequence in the window of comparison and multiplying the result by 100 to yield the percentage of sequence homology.
  • Homology is evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85 (8) : 2444-2448; Altschul et al., 1990, J. Mol. Biol.
  • BLAST Basic Local Alignment Search Tool
  • treat refers to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated, although not precluded, treating a disorder or condition does not require that the disorder, condition, or symptoms associated therewith be completely eliminated. In certain embodiments, treatment includes prevention of a disorder or condition, and/or symptoms associated therewith.
  • stroke indicates a medical condition in which poor blood flow to the brain results in cell death. It includes but not limited to ischemic stroke and hemorrhagic stroke.
  • hemorhagic shock refers to a condition of reduced tissue perfusion, resulting in the inadequate delivery of oxygen and nutrients that are necessary for cellular function.
  • acute mountain sickness refers to a condition developed when exposed to high altitudes having low levels of oxygen and decreased air pressure.
  • ischemic disease refers to diseases and/or conditions characterized by reduced oxygenation to any tissue in the body such as, but not limited to, ischemic heart disease, transient ischemic attack, cardiac ischemia, stroke, reperfusion injury, bowel ischemia, intestinal ischemia, peripheral artery disease, critical limb ischemia, mesenteric ischemia, brain ischemia, leg ischemia, myocardial infarction, peripheral vascular disease, coronary artery disease, angina, wound healing, renal artery disease, diabetic ulcer healing, congestive heart failure, and hepatic ischemia.
  • Ischemia can be caused by a number of conditions including, but not limited to, anemia, stroke and atherosclerosis. Multiple diseases result from ischemia including, for example, cerebrovascular ischemia, renal ischemia, pulmonary ischemia, limb ischemia, myocardial ischemia, and ischemic cardiomyopathy.
  • peripheral artery disease refers to a condition of narrowing of the peripheral arteries, such as those serving the legs, stomach, arms and/or head.
  • PAD includes a wide range of vascular diseases caused by atherosclerotic, thromboembolic, and inflammatory processes that alter the structure and function of the arteries. The most common cause of PAD is atherosclerosis.
  • p50 value indicates the oxygen tension at which hemoglobin is 50%saturated. Values of p50 are negatively correlated with substrate affinity; lower values correspond to higher affinity and vice versa.
  • oxygen carrying capacity indicates the capability of a composition to carry oxygen.
  • the capability to carry oxygen comprises but not limited to two aspects: compositions containing recombinant hemoglobins with lower oxygen affinity are used when rapid oxygenation is desired in cases of tissue hypoxia resulting from extensive blood loss (e.g., hemorrhagic shock) .
  • Lower oxygen affinity means that the material can “offload” oxygen to a target more easily than a material with a higher oxygen affinity.
  • Compositions with higher oxygen affinity are useful as oxygenation adjunct therapies in cancer treatment where a slower delivery rate of oxygen is desired in that case.
  • “Improved oxygen carrying capacity” means the level of oxygen carried by a composition is increased regardless of rapid oxygenation or low delivery of oxygen.
  • co-transform refers to a process that transfers more than one plasmids or vectors bearing exogenous DNA into the host cell at the same time.
  • the host cells generally include but are not limited to bacterial, yeast, insect, mammalian, and plant cells. Any other reasonable host cells for accepting plasmids or vectors bearing exogenous DNA are also within the contemplation of the present disclosure.
  • the methods for transformation of a DNA construct into a host cell include but not limited to chemical transformation, electroporation or particle bombardment. Any other reasonable methods for transforming a DNA construct into a host cell are also within the contemplation of the present disclosure.
  • plasmid As used herein, the terms “plasmid” , “expression plasmid” , “vector” , “DNA construct” and the like are used interchangeably herein to refer to a genetic structure that carries one or more exogenous DNA sequences of interest, as well as other functional DNA segments and/or sites, such as promoter segment, restriction site, 5’ primer site, 3’ primer site, origin of replication segment, antibiotic resistance gene segment, selectable marker segment, etc. These genetic structures are typically, but not always, circular DNA molecules, which are physically separated from a chromosomal DNA and can replicate independently.
  • exogenous DNA refers to deoxyribonucleic acid that originates outside of the host cells, including but not limited to the genes encoding particular proteins of interest or subunits thereof.
  • recombinant hemoglobin expression plasmid as used herein can refer to a plasmid that carries a polynucleotide sequence encoding one di-alpha chain, a plasmid that carries a polynucleotide sequence encoding one or two beta chains, or a plasmid that carries a polynucleotide sequence encoding a di-alpha chain and a beta chain.
  • HemH refers to any enzyme, such as ferrochelatase, that catalyzes the production of heme.
  • Heme-transporter refer proteins that facilitate the uptake of heme and/or iron, and such proteins include, but are not limited to, ChuA, TonB, heme carrier protein 1 (HCP1) , divalent metal transporter 1 (DMT1) , mucolipin-1 (also known as TRPML1) , HRG1, and hemopexin.
  • HemH plasmid refers to a plasmid that carries a polynucleotide sequence encoding any enzyme, such as ferrochelatase, that catalyzes the production of heme, and the polynucleotide may include one or more nucleotide modifications.
  • Heme-transporter plasmid (s) refer to one or more plasmids that carry one or more polynucleotide sequences encoding one or more proteins that facilitate the uptake of heme and/or iron, and such proteins include, but are not limited to, ChuA, TonB, heme carrier protein 1 (HCP1) , divalent metal transporter 1 (DMT1) , mucolipin-1 (also known as TRPML1) , HRG1, and hemopexin.
  • the di-alpha chain can comprise a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1.
  • Polypeptides having at least 98.93%sequence homology to SEQ ID NO: 1 can refer to polypeptides having at most three amino acid modifications, i.e. zero, one, two, or three amino acid modifications with respect to the SEQ ID NO: 1.
  • the di-alpha chain comprises a polypeptide sequence having at least 99.29%sequence homology with the SEQ ID NO: 1.
  • Polypeptides having at least 99.29%sequence homology can have at most two amino acid modifications, i.e. zero, one, or two amino acid modifications with respect to the SEQ ID NO: 1.
  • the di-alpha chain comprises a polypeptide sequence having at least 99.64%sequence homology with the SEQ ID NO: 1.
  • Polypeptides having at least 99.64%sequence homology can have at most one amino acid modifications, i.e. zero or one amino acid modification with respect to the SEQ ID NO: 1.
  • the di-alpha chain comprises a polypeptide sequence of SEQ ID NO: 1.
  • the di-alpha chain consists of a polypeptide sequence of SEQ ID NO: 1.
  • the one, two, or three amino acid modifications can occur at any amino acid present in SEQ ID NO: 1, except the positions 1, 29, 58, 143, 171, and 200 of SEQ ID NO: 1, in which position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine.
  • the polypeptide sequence of the di-alpha chain can contain a linker that connects the N-terminal of a first alpha subunit with the C-terminal of a second alpha subunit or the N-terminal of a first alpha subunit is directly connected to the C-terminal of a second alpha subunit.
  • the linker can be one or more amino acid residues selected from the group consisting of glycine and serine.
  • the linker is (Gly-Ser) n , (Gly-Gly-Gly-Ser) n , (Gly-Gly-Ser-Gly) n , (Gly-Gly-Gly-Gly-Ser) n , (Gly-Gly-Ser) n or Gly n , wherein n is 1-10.
  • the linker is Gly n linker, wherein n is 1-4. In certain embodiments, the linker is Gly.
  • Each of the two beta chains can comprise a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 2.
  • Polypeptides having at least 97.94%sequence homology can have at most three amino acid modifications, i.e. zero, one, two, or three amino acid modifications with respect to the SEQ ID NO: 2.
  • each of the two beta chains comprises a polypeptide sequence having at least 98.63%sequence homology with the SEQ ID NO: 2.
  • Polypeptides having at least 98.63%sequence homology can have at most two amino acid modifications, i.e. zero, one, or two amino acid modifications with respect to the SEQ ID NO: 2.
  • each of the two beta chains comprises a polypeptide sequence having at least 99.31%sequence homology with the SEQ ID NO: 2.
  • Polypeptides having at least 99.31%sequence homology can have at most one amino acid modifications, i.e. zero or one amino acid modification with respect to the SEQ ID NO: 2.
  • each of the two beta chains comprises a polypeptide sequence of SEQ ID NO: 2.
  • the one, two, or three amino acid modifications can occur at any amino acid present in SEQ ID NO: 2, except the position 1 of the SEQ ID NO: 2, which must be methionine.
  • each of the two beta chains can comprise a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 3.
  • Polypeptides having at least 97.94%sequence homology can refer to polypeptides having at most three amino acid modifications, i.e. zero, one, two, or three amino acid modifications with respect to the SEQ ID NO: 3.
  • each of the two beta chains comprises a polypeptide sequence having at least 98.63%sequence homology with the SEQ ID NO: 3.
  • Polypeptides having at least 98.63%sequence homology can have at most two amino acid modifications, i.e. zero, one, or two amino acid modifications with respect to the SEQ ID NO: 3.
  • each of the two beta chains comprises a polypeptide sequence having at least 99.31%sequence homology with the SEQ ID NO: 3.
  • Polypeptides having at least 99.31%sequence homology can have at most one amino acid modifications, i.e. zero or one amino acid modification with respect to the SEQ ID NO: 3.
  • each of the two beta chains comprises a polypeptide sequence of SEQ ID NO: 3.
  • the one, two, or three amino acid modifications can occur at any amino acid present in SEQ ID NO: 3, except the positions 1, 82, and 108 of the SEQ ID NO: 3, in which position 1 of the SEQ ID NO: 3 must be methionine, the position 82 of the SEQ ID NO: 3 must be aspartic acid, and the position 108 of the SEQ ID NO: 3 must be lysine.
  • Di-alpha chain having a polypeptide sequence of SEQ ID NO: 11 and two of the beta chains having a polypeptide sequence of SEQ ID NO: 12 form the recombinant hemoglobin TBN.
  • Di-alpha chain having a polypeptide sequence of SEQ ID NO: 1 and two of the beta chains having a polypeptide sequence of SEQ ID NO: 2 form the recombinant hemoglobin TBM1.
  • Di-alpha chain having a polypeptide sequence of SEQ ID NO: 1 and two of the beta chains having a polypeptide sequence of SEQ ID NO: 3 form the recombinant hemoglobin TBM9.
  • PPIX concentrations of TBN, TBM1, and TBM9 prepared under identical conditions are listed in Table 1.
  • the p50 level, tetramer purity, met-hemoglobin (Met-Hb) %and heme/protein ratio are shown in Table 2.
  • the methods for preparing the recombinant hemoglobins described herein are simplified and cost effective. Without wishing to be bound by theory, it is believed that the mutations of the di-alpha chain and beta chain lead to structural changes of the recombinant hemoglobins, which affects the kinetics of the incorporation of heme and PPIX, and ultimately changes the percentage of PPIX in the purified recombinant hemoglobins.
  • the present disclosure also relates to methods for expressing, fermenting, and purifying the recombinant hemoglobins described herein.
  • the method comprises co-expressing the plasmids encoding the recombinant hemoglobins described herein, a ferrochelatase (HemH) plasmid, and a Heme-transporter plasmid in the host cells.
  • Different host cells listed in Table 3 were tested, and among the host cells, JM109 (DE3) (with lambda DE3) (i.e. JM109 E. coli bacterial strain with lambda DE3) , BL21-T7 or AI E. coli bacterial strain (without lambda DE3) and T7 Competent E.
  • the HemH plasmid can be wildtype or contain certain mutations.
  • the Heme-transporter plasmid can be constructed by inserting the E. coli heme-utilization gene (ChuA) into a vector.
  • the ChuA gene encodes a 69 kDa outer membrane protein, which facilitates the uptake of heme in E. coli.
  • the uptake of heme by ChuA is dependent on an inner membrane protein named TonB.
  • the methods described herein preferably comprise a step of co-transforming the recombinant hemoglobin plasmids, the HemH plasmid, the ChuA plasmid, and the TonB plasmid into the selected host cells, i.e. JM109 E. coli bacterial strain with lambda DE3, BL21-T7 or AI E. coli bacterial strain without lambda DE3 and SHuffle E. coli bacterial strain without lambda DE3.
  • the method can also co-transform the ChuA plasmid alone together with the recombinant hemoglobin plasmids and the HemH plasmid into the selected host cells.
  • the gene encoding the ferrochelatase (HemH) and the Heme-transporter can also be inserted into genome of E. coli bacterial strain by CRISPR/Cas9 genome editing method to endogenously express ferrochelatase (HemH) and the Heme-transporter.
  • CRISPR/Cas9 genome editing method to endogenously express ferrochelatase (HemH) and the Heme-transporter.
  • BL21-T7 and Jm109-T7 E. coli bacterial strain were modified to BL21-T7-CT (CRISPR/Cas9) and Jm109-T7-CT (CRISPR/Cas9) bacterial strains to express recombinant hemoglobin proteins.
  • the method further comprises a purification step that advantageously does not require a heat step, and does not use carbon monoxide.
  • the steps for purification are shown in FIG 6.
  • the recombinant hemoglobins prepared using the methods described herein can have reduced amounts of protoporphyrin-IX (PPIX) , e.g., less than 1% (by weight) , shown in Table 1.
  • the recombinant hemoglobins prepared using the methods described herein have between 0.08%and 1%, 0.11%and 1%, 0.08%and 0.20%, 0.08%and 0.15%, or 0.08%and 0.11% (by weight) of PPIX.
  • the methods described herein are simpler as compared with existing methods for recombinant hemoglobin preparation, and can result in higher yield of soluble recombinant hemoglobin with reduced levels of impurities.
  • the present disclosure further relates to pharmaceutical compositions comprising the recombinant hemoglobins described herein and at least one pharmaceutically acceptable carrier.
  • the pharmaceutical composition comprises other excipients, such as amino acids and sugar.
  • the present disclosure further relates to a polynucleotide sequence encoding a di-alpha chain as described herein.
  • the polynucleotide sequence encodes a di-alpha chain comprising a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine.
  • the polynucleotide sequence encodes a di-alpha chain comprising a polypeptide sequence having at least 99.29%sequence homology with the SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine.
  • the polynucleotide sequence encodes a di-alpha chain comprising a polypeptide sequence having at least 99.64%sequence homology with the SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine.
  • the polynucleotide sequence encodes a di-alpha chain comprising a polypeptide sequence of SEQ ID NO: 1.
  • the polynucleotide sequence encodes a di-alpha chain consisting of a polypeptide sequence of SEQ ID NO: 1.
  • the present disclosure further relates to a polynucleotide sequence encoding a beta chain as described herein.
  • the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 2.
  • the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence having at least 98.63%sequence homology with the SEQ ID NO: 2.
  • the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence having at least 99.31%sequence homology with the SEQ ID NO: 2.
  • the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence comprising a polypeptide sequence of SEQ ID NO: 2. In certain embodiments, the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence consisting of a polypeptide sequence of SEQ ID NO: 2.
  • the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 3 In certain embodiments, the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence having at least 98.63%sequence homology with the SEQ ID NO: 3. In certain embodiments, the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence having at least 99.31%sequence homology with the SEQ ID NO: 3. In certain embodiments, the polynucleotide sequence encodes a beta chain comprising a polypeptide sequence comprising a polypeptide sequence of SEQ ID NO: 3.
  • the acid modifications can occur at any amino acid present in SEQ ID NO: 3, except the positions 1, 82, and 108 of the SEQ ID NO: 3, in which position 1 of the SEQ ID NO: 3 must be methionine, the position 82 of the SEQ ID NO: 3 must be aspartic acid, and the position 108 of the SEQ ID NO: 3 must be lysine.
  • the polynucleotide sequence encodes a di-alpha chain as described herein and a beta chain as described herein.
  • the di-alpha chain comprises a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine; and the two beta chains comprises a polypeptide sequence having at least 99.31%sequence homology with SEQ ID NO: 2, wherein the amino acid at position 1 must be methionine; or a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 3, wherein the amino acid at position 1 must be methionine, the amino acid at position 82 must be aspartic acid,
  • a vector is a typically includes additional sequences, including sequences that direct propagation of the vector in the cell or insertion of part of the vector into the cell's genome, and a gene which allows an individual to screen for the presence of the vector.
  • vectors include plasmids, artificial chromosomes, viruses, and linear polynucleotide fragments which are designed to insert into a cell's genome.
  • Vectors are well known tools to a person of ordinary skill in the art, and a person of ordinary skill in the art can easily find appropriate vectors for a particular organism in the literature or in biobanks, such as ATCC.
  • a vector comprising a polynucleotide sequence encoding at least one of a di-alpha chain described herein and a beta chain as described herein.
  • the vector is a plasmid, artificial chromosomes, viruses, or a linear polynucleotide fragment, which is designed to insert into a cell's genome.
  • the present disclosure further relates to a system for producing a recombinant hemoglobin as described herein, the system comprising: an Escherichia coli or non-Escherichia coli host cell comprising: a polynucleotide encoding HemH; a polynucleotide encoding Heme-transporter; a polynucleotide encoding a di-alpha chain; and a polynucleotide encoding a beta chain; wherein the di-alpha chain comprises a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine; and the beta chain comprises a polypeptide sequence having at least 99.
  • the polynucleotide encoding HemH; the polynucleotide encoding Heme-transporter; the polynucleotide encoding the di-alpha chain; and the polynucleotide encoding the beta chain are present in one or more vectors selected from the group consisting of a plasmid, artificial chromosomes, viruses, and linear polynucleotide fragments which are designed to insert into a cell's genome.
  • the polynucleotide encoding HemH; the polynucleotide encoding Heme-transporter; the polynucleotide encoding the di-alpha chain; and the polynucleotide encoding the beta chain are inserted into the host cell’s genome using CRISPR/CAS 9.
  • the polynucleotide encoding HemH; the polynucleotide encoding Heme-transporter; the polynucleotide encoding the di-alpha chain; and the polynucleotide encoding the beta chain are present in the host cell in one or more plasmids.
  • the system for producing the recombinant hemoglobin as described herein comprises: an Escherichia coli or non-Escherichia coli host cell comprising: a first plasmid comprising a polynucleotide encoding HemH, a di-alpha chain, and two beta chains, wherein the di-alpha chain comprises a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine; and the two beta chains comprises a polypeptide sequence having at least 99.31%sequence homology with SEQ ID NO: 2, wherein the amino acid at position 1 must be methionine; or a polypeptide sequence having at least 97
  • the vectors described herein can further comprise one or more polynucleotides encoding a promoter, an operator, and a selectable marker.
  • Any promoter can be used in the vectors described herein.
  • the selection of the appropriate promoter is well within the skill of a person of ordinary skill in the art.
  • Exemplary promoters include, but are not limited to, lac, trp, tac, trc, ara, araB, T5, T7, and T7lac.
  • Operators can include the lac operator, the ⁇ operator, the trp operator, the gal operator, the ara operator, and the Arg operator. If desired, the corresponding promoter may be functionally associated with its operator.
  • a selectable marker can be a polynucleotide sequence that allows selection for or against a molecule or a cell that contains it, often under particular conditions. These markers can encode an activity, such as, but not limited to, production of RNA, peptide, or protein, or can provide a binding site for RNA, peptides, proteins, inorganic and organic compounds or compositions and the like. Any selectable marker in the art can be used in connection with the expression systems and methods described herein.
  • Exemplary selectable markers include, but are not limited to, polynucleotide sequences that encode products which provide resistance against otherwise toxic compounds, such as antibiotics; polynucleotide sequences that encode a product which is otherwise lacking in the recipient cell, such as tRNA genes, auxotrophic markers) ; polynucleotide sequences that encode a product which suppresses the activity of a gene product; polynucleotide sequences that encode products which can be readily identified (e.g., phenotypic markers, such as ⁇ -galactosidase, green fluorescent protein (GFP) , and cell surface proteins) ; and the like.
  • phenotypic markers such as ⁇ -galactosidase, green fluorescent protein (GFP) , and cell surface proteins
  • the selectable marker is a polynucleotide sequence that confers resistance against an antibacterial agent, such as ampicillin, kanamycin, erythromycin, chloramphenicol, gentamycin, kasugamycin, rifampicin, spectinomycin, D-Cycloserine, nalidixic acid, streptomycin, tetracycline, and the like.
  • an antibacterial agent such as ampicillin, kanamycin, erythromycin, chloramphenicol, gentamycin, kasugamycin, rifampicin, spectinomycin, D-Cycloserine, nalidixic acid, streptomycin, tetracycline, and the like.
  • the present disclosure further relates to a method of producing the recombinant hemoglobin as described herein, comprising the steps of: (a) providing a host cell comprising a polynucleotide encoding the di-alpha chain and a polynucleotide encoding the two beta chains; and (b) inducing the host cell containing the polynucleotide encoding the di-alpha chain and the polynucleotide encoding the two beta chains to express recombinant hemoglobin thereby producing the recombinant hemoglobin.
  • the polynucleotide encoding HemH; the polynucleotide encoding Heme-transporter; the polynucleotide encoding the di-alpha chain; and the polynucleotide encoding the two beta chains are present in one or more vectors selected from the group consisting of a plasmid, artificial chromosomes, viruses, and linear polynucleotide fragments which are designed to insert into a cell's genome.
  • the polynucleotide encoding HemH; the polynucleotide encoding Heme-transporter; the polynucleotide encoding the di-alpha chain; and the polynucleotide encoding the two beta chains are inserted into the host cell’s genome using CRISPR/CAS 9.
  • the polynucleotide encoding HemH; the polynucleotide encoding Heme-transporter; the polynucleotide encoding the di-alpha chain; and the polynucleotide encoding the two beta chains are present in the host cell in one or more plasmids.
  • the method of producing the recombinant hemoglobin described herein comprises: (a) providing a host cell comprising one or more recombinant hemoglobin expression plasmids encoding the di-alpha chain and the two beta chains; and (b) inducing the host cell containing the one or more recombinant hemoglobin expression plasmids encoding the di-alpha chain and the two beta chains to express recombinant hemoglobin thereby producing the recombinant hemoglobin.
  • the one or more recombinant hemoglobin expression plasmids encoding the di-alpha chain and the two beta chains comprise a polynucleotide sequence of SEQ ID NO: 4 and a polynucleotide sequence of SEQ ID NO: 5.
  • the one or more recombinant hemoglobin expression plasmids encoding the di-alpha chain and the two beta chains comprises a polynucleotide sequence of SEQ ID NO: 4 and a polynucleotide sequence of SEQ ID NO: 6.
  • the host cell is selected from the group consisting of JM109 E. coli bacterial strain with lambda DE3, BL21-AI E. coli bacterial strain without lambda DE3, and SHuffle E. coli bacterial strain without lambda DE3.
  • the host cell further comprises a plasmid encoding HemH.
  • the host cell further comprises one or two plasmids encoding a Heme-transporter.
  • a host cell comprising at least one vector described herein encoding at least one polypeptide selected from a di-alpha chain as described herein and two beta chains as described herein.
  • the at least one vector is a plasmid.
  • the host cell comprises one or more plasmids.
  • Recombinant hemoglobins can be formed by expressing one di-alpha chain and two beta chains inside a host cell in the presence of heme.
  • Different host cells are tested and shown in Table 3.
  • the host cell is JM109 E. coli bacterial strain with lambda DE3, BL21-T7 or AI E. coli bacterial strain without lambda DE3, or SHuffle E. coli bacterial strain without lambda DE3 as they have the best yield, or BL21-T7-CT (CRISPR/Cas9) and Jm109-T7-CT (CRISPR/Cas9) as they have the best quality and easy manipulation.
  • the expression of the di-alpha chain and beta chains can be realized by co-transforming a plasmid carrying the polynucleotide sequence that encodes one di-alpha polypeptide chain, and a plasmid carrying the polynucleotide sequence that encodes two beta polypeptide chains together into the host cell, wherein the ratio of the plasmid for di-alpha polypeptide chain and the plasmid for two beta polypeptide chains is approximately 1: 1.
  • the expression of the di-alpha chain and beta chains can also be realized by co-transforming a plasmid carrying the polynucleotide sequence that encodes one di-alpha polypeptide chain, and a plasmid carrying the polynucleotide sequence that encodes one beta polypeptide chain together into the host cell, wherein the ratio of the plasmid for di-alpha polypeptide chain and the plasmid for one beta polypeptide chain is approximately 1: 2.
  • the expression of the di-alpha chain and beta chain can also be realized by transforming a plasmid carrying both the polynucleotide sequence that encodes one di-alpha polypeptide chain and the polynucleotide sequence that encodes two beta chains into the host cells.
  • the plasmid for expressing the recombinant hemoglobins described herein comprise a polynucleotide encoding a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine; and two beta chains, each of which comprises a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 2, wherein position 1 of SEQ ID NO: 2 must be methionine.
  • the plasmid for expressing the recombinant hemoglobin comprises a polynucleotide sequence of SEQ ID NO: 4 (di-alpha chain for TBM1 and TBM9) and a polynucleotide sequence of SEQ ID NO: 5 (beta chain for TBM1) .
  • the plasmid maps are shown in FIG. 2A.
  • the host cell is K12 strain ( T7 Competent E. coli) .
  • the plasmid for expressing the recombinant hemoglobin comprises a polynucleotide sequence of SEQ ID NO: 4 (di-alpha chain for TBM1 and TBM9) and a polynucleotide sequence of SEQ ID NO: 5 (beta chain for TBM1) and the host cell is K12 strain (NEB#C3026) .
  • the plasmid for expressing the recombinant hemoglobins described herein comprise a polynucleotide encoding a polypeptide sequence having at least 98.93%sequence homology with SEQ ID NO: 1, wherein the amino acids at position 1 and position 143 of SEQ ID NO: 1 must be methionine, the amino acids at position 29 and position 171 of SEQ ID NO: 1 must be phenylalanine, and the amino acids at position 58 and position 200 of SEQ ID NO: 1 must be glutamine; and two beta chains, each of which comprises a polypeptide sequence having at least 97.94%sequence homology with SEQ ID NO: 3, wherein position 1 of SEQ ID NO: 3 must be methionine, position 82 of SEQ ID NO: 3 must be aspartic acid, and position 108 of SEQ ID NO: 3 must be lysine.
  • the plasmid for expressing the recombinant hemoglobin comprises a polynucleotide sequence of SEQ ID NO: 4 (di-alpha chain for TBM1 and TBM9) and a polynucleotide sequence of SEQ ID NO: 6 (beta chain for TBM9) (the plasmid maps are shown in FIG. 2A) and the host cell is K12 strain ( T7 Competent E. coli) .
  • the plasmids for expressing di-alpha chain, beta chains and/or a combination thereof are co-transformed with the plasmid for expressing ferrochelatase or any other enzyme that catalyzes the production of heme.
  • the plasmid for expressing ferrochelatase or any other enzyme that catalyzes the production of heme is a HemH plasmid, wherein the HemH plasmid can contain any HemH nucleotide.
  • An exemplary HemH mutant polynucleotide is listed in FIG. 7.
  • the HemH plasmid has a polynucleotide sequence of SEQ ID NO: 7 (wildtype) or SEQ ID NO: 8 (mutant) .
  • hemin is added into the solution containing host cells that have been transformed with the plasmids expressing di-alpha chain, beta chains and/or a combination thereof.
  • a plasmid for expressing a heme transporter is also co-tranformed together with the plasmid for expressing the recombinant hemoglobin and/or the plasmid for expressing heme production enzymes.
  • the heme transporter can be any protein that can facilitate the uptake of heme, including but not limited to a 69 kDa outer membrane protein encoded by the ChuA gene, and an inner membrane protein named TonB, on which the uptake of heme by ChuA is dependent.
  • HCP1 heme carrier protein 1
  • DMT1 divalent metal transporter 1
  • TRPML1 mucolipin-1
  • HRG1 hemopexin, and the like are also within the contemplation of the present disclosure.
  • the Heme-transporter plasmid comprises a polynucleotide sequence having 98%sequence homology with SEQ ID NO: 9.
  • the DNA sequence of ChuA is shown in FIG. 8.
  • the Heme-transporter plasmid comprises a polynucleotide sequence having 99%sequence homology with SEQ ID NO: 9.
  • the Heme-transporter plasmid comprises a polynucleotide sequence of SEQ ID NO: 9.
  • the Heme-transporter plasmid comprises a polynucleotide sequence having 98%sequence homology with SEQ ID NO: 10.
  • the DNA sequence encoding TonB is shown in FIG. 9.
  • the Heme-transporter plasmid comprises a polynucleotide sequence having 99%sequence homology with SEQ ID NO: 10.
  • the Heme-transporter plasmid comprises a polynucleotide sequence of SEQ ID NO: 10.
  • only the Heme-transporter plasmid bearing the ChuA is co-transformed with the plasmids for expressing di-alpha chain, beta chains and/or a combination thereof.
  • only the Heme-transporter plasmid bearing the ChuA is co-transformed with the plasmids for expressing di-alpha chain, beta chains and/or a combination thereof, and the plasmid for expressing heme production enzymes.
  • both the plasmid bearing the ChuA gene and the plasmid for expressing TonB are co-transformed with the plasmids for expressing di-alpha chain, beta chains and/or a combination thereof.
  • both the plasmid bearing the ChuA gene and the plasmid for expressing TonB are co-transformed with the plasmids for expressing di-alpha chain, beta chains and/or a combination thereof, and the plasmid for expressing heme production enzymes.
  • the pETDuet-1 vector has two T7 promoters.
  • the first T7 promoter is T1 and the second T7 promoter is T2.
  • the proteins can be expressed under the control of either T1 or T2 of the pETDuet-1 vector.
  • the pRSFDuet-1 vector has two T7 promoters, and the first T7 promoter is R1 and the second T7 promoter is R2.
  • the proteins can be expressed under the control of either T1 or T2 of the pRSFDuet-1 vector.
  • the components for the expression system contain (1) T7 promoter/lac operator and (2) sequence for protein expression including start codon and stop codon.
  • Each of Duet plasmid has two T7 promoter/lac operator (T1 and T2) .
  • T1 and T2 T7 promoter/lac operator
  • the antibiotic resistance and replicons of plasmid were shown in Table 4. Clone no. 12 and 19 show the best yield and quality of recombinant hemoglobin.
  • st plasmid 1 st plasmid is pETDuet-1 (ampicillin) which expressed di-alpha and beta chain under T1 and HemH under T2; 2 nd plasmid is pRSFDuet-1 (kanamycin) which expressed ChuA and TonB under R2.
  • 1 st plasmid is pETDuet-1-Kana (kanamycin) which expressed di-alpha and beta chain under T1 and HemH under T2; 2 nd plasmid is pACYCDuet-1 (chloramphenicol) which expressed ChuA and TonB under A2.
  • the host cells containing one or more of the above-mentioned plasmids can be incubated and fermented using any method known to those of skill in the art.
  • the recombinant hemoglobins produced by the bacterial cells can then be purified using a simplified procedure, which does not require a heat step, and does not require the use of carbon monoxide (FIG. 6) .
  • the recombinant hemoglobins can be purified using the purification procedure described herein and can yield purified hemoglobin containing little or no HbCO, and having low amounts of PPIX, e.g., less than 1%.
  • the UPLC results indicate that the heme: protein ratio is higher for TBM1 and TBM9, and highest for TBM9 (Table 2) .
  • the High Performance Liquid Chromatography (HPLC) results indicate the octamer: tetramer: dimer distribution of TBN, TBM1 and TBM9, as shown in Table 5 below.
  • Purification of the recombinant hemoglobins described herein can yield the protein product in high purity even without the step of heat treatment, as shown in FIG. 4 and Tables 1 and 2.
  • Such unexpected technical effect solves one or more problems of the existing methods for preparing recombinant hemoglobins.
  • the stability of the recombinant hemoglobins described herein during the purification will not be affected and thus CO will not be required to maintain the stability of recombinant hemoglobins during heat treatment. Accordingly, an additional step to remove the undesired CO is not required.
  • the purification process for the recombinant hemoglobins described herein do not require heat treatment and CO removal, hence making the process simpler, less costly, and more industrially applicable.
  • the recombinant hemoglobins prepared using the methods described herein were injected in a mouse model to measure the liver oxygen level for 180 min (FIG. 3) .
  • Results showed that the recombinant hemoglobin TBM1, wherein the di-alpha chain has SEQ ID NO: 1 and the two beta chains have SEQ ID NO: 2, significantly increased the liver oxygen pressure at 30 min after being administered, as compared to the control group where buffer was administered and the YQ (bovine crossed-linked hemoglobin, batch no. ER007) was administered (FIG. 3B) .
  • liver oxygen pressure reaches a plateau at 20-30 min after administering TBM9 and reaches a plateau at about 70 min after administering TBM1, both of which are higher than the plateaus reached by administering YQ, buffer, or TBN (wherein the di-alpha chain has SEQ ID NO: 11, and the two beta chains have SEQ ID NO: 12, as shown in FIG. 1) .
  • TBN di-alpha chain has SEQ ID NO: 11, and the two beta chains have SEQ ID NO: 12, as shown in FIG. 1 .
  • the p50 values of TBN, TBM1, and TBM9 are summarized in Table 6.
  • the recombinant hemoglobins described herein may be prepared as a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers can comprise diluents, adjuvants, excipients, vehicles, or a combination thereof with which the active compound is administered.
  • Such vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. For example, 0.4%saline and 0.3%glycine can be used.
  • such vehicle is sucrose or trehalose. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration) .
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, thickening, lubricating and coloring agents, etc.
  • concentration of the protein in such pharmaceutical formulation can vary widely, e.g., from less than about 0.5%, usually at or at least about 1%to as much as 15 or 20%by weight and will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the particular mode of administration selected.
  • Suitable vehicles and formulations comprise sucrose, trehalose, amino acid, phosphate buffer.
  • the recombinant hemoglobins described herein can be used as an agent for oxygenating in vivo or ex vivo tissues. Such agents are useful in the treatment of any disease or condition in which oxygen deficiency is the cause of the disease and/or condition, or oxygen deficiency is related to the treatment efficacy of the disease and/or condition.
  • These diseases or conditions include, but not limited to, cancer, stroke, hemorrhagic shock, AMS, PAD, PD and, chronic obstructive pulmonary disease (COPD) , emphysema, bronchitis, pneumonia, pulmonary edema, anemia, asthma, heart disease, diabetes, cystic fibrosis, epilepsy and seizures, inflammatory bowel disease (IBD) , and Raynaud’s disease.
  • COPD chronic obstructive pulmonary disease
  • the present disclosure also provides expression clones that can, e.g., improve the purity of recombinant hemoglobins described herein.
  • the purified protein expressed using the previous expression clone bearing nucleotide sequences of HemH and TBN, TBM1, or TBM9 has a peak for PPIX in the UPLC-PDA analysis, whereas such peak disappeared for the purified protein expressed using the new improved expression clone bearing nucleotide sequences of HemH mutant, Heme transporter system (ChuA and TonB) , and TBN, TBM1, or TBM9.
  • the 2, 3-DPG is added to the recombinant hemoglobin solution.
  • the p50 value of human recombinant hemoglobin in the presence of 2, 3-DPG increased as compared to the human recombinant without 2,3-DPG (FIG. 5B) .
  • the plasmids were constructed in a conventional cloning method and the vectors and restriction enzyme cute sites used for each of the plasmids are indicated in the Table 8 below.
  • the desired plasmids were transformed into the desired strains. From a fresh culture plate, colonies were picked and placed in a 15 ml tube containing 2 ml LB medium and appropriate antibiotic (Kanamycin 50 ⁇ g/ml; Chloramphenicol 34 ⁇ g/ml) and grown at 32°C overnight, 250 rpm. The resulting cultures were diluted 1: 100 into 10 ml TB medium with appropriate antibiotics in 50 ml falcon. When OD 600 reached 0.6, target proteins were induced by 0.4 mM IPTG at 25°C. After 20 h induction, the bacteria were harvest by centrifugation at 4000 x g for 15 min.
  • E. coli clones transformed with desired plasmids were inoculated into 200 ml of seed culture medium (6%yeast extract and 1%NaCl) and cultivated at 32°C with shaking at 250 rpm for overnight. The fermentation was performed in 10-L bioreactor (Sartorius C plus) .
  • the flask of seed culture was inoculated into 6.5 L of medium (1%yeast extract, 1.6%tryptone, 15 mM K 2 HPO 4 , 37 mM KH 2 PO 4 , 15 mM NaCl, 15 mM (NH 4 ) 2 SO 4 , 2 mM L-proline, 2%glycerol) in a 10-L bioreactor with a final OD 600 at 0.05 and cultivated at 32°C and pH 7.0 with airflow of 6 L/min and initial stir rate at 400 rpm, in which dissolved oxygen was maintained above 20%.
  • medium 1%yeast extract, 1.6%tryptone, 15 mM K 2 HPO 4 , 37 mM KH 2 PO 4 , 15 mM NaCl, 15 mM (NH 4 ) 2 SO 4 , 2 mM L-proline, 2%glycerol
  • the fed-batch process of recombinant protein production in 10-L bioreactor was divided into two phases.
  • the 1 st phase was aerobic batch cultivation at 32°C for 7 h.
  • the 2 nd Phase was an induction process at 25°C for 18 h using isopropyl- ⁇ -d-thiogalactoside (IPTG) at a final concentration of 0.4 mM with OD 600 of bacteria at 4.0 to induce the expression of recombinant protein.
  • IPTG isopropyl- ⁇ -d-thiogalactoside
  • a fed-batch cultivation at 25°C for 18 h in which 80 g/L glycerol and 100 mg/L Hemin was fed continuously to maintain the required specific growth rate of bacteria with airflow of 8 L/min and stir rate at 600-800 rpm, in which dissolved oxygen was maintained ⁇ 4%.
  • the bacteria at final OD 600 of 30-40 were harvested by centrifugation and stored in -80 °C for future use.
  • Cell pellet from 10 ml TB medium was suspended in a phosphate buffer (pH 7.4) and disrupted by 0.1 mm glass beads.
  • the soluble protein was harvested by centrifugation at 15000 x g for 15 min at 4°C.
  • the target protein bound to nickel charged beads and eluted by 0.4 M Imidazole.
  • the cell pellet from fermentation was resuspended in a solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.5) in 1 g cell to 7 ml buffer ratio.
  • the suspension was processed through a high-pressure homogenizer at 800 bar (two cycles) .
  • the cell lysate was clarified by hollow fiber system.
  • the soluble fraction was passed through a series of chromatographic columns to isolate the TBN, TBM1, or TBM9 proteins.
  • the supernatant was loaded onto zinc affinity column. After sufficient column wash with buffer (20 mM Tris, 30 mM NaCl, pH 8.5) , the target proteins were eluted by elution buffer (20 mM Tris, 100 mM imidazole, pH 8.3) .
  • the recovered fraction was loaded onto DEAE anion-exchange column.
  • the target proteins were eluted by elution buffer (20 mM NaPi, pH 6.0) .
  • the purified TBN/TBM1/TBM9 samples were concentrated to 50 mg/ml.
  • the protein samples were lyophilized with appropriate excipients in a glass vial.
  • the protein concentrations of the samples were measured by Bradford protein assay. Samples were diluted to protein concentration of about 10 mg/ml. A 50 ⁇ l of purified protein was mixed with 400 ⁇ l acidic acetone. After vigorous stirring, the mixture was separated by centrifugation. Acetonitrile (ACN, 400 ⁇ l, sample to organic solvent equals 1: 8) was added into the solution, followed by centrifugation at 14,000 rpm for 5 min. Samples were then applied to UPLC analysis (Acquity H-class UPLC system; Waters, Milford, MA, USA) .
  • UPLC analysis Acquity H-class UPLC system
  • PPIX was separated by Waters Acquity BEH C18 1.7 ⁇ m, 2.1 ⁇ 50mm Column at 0.40 ml/min at 25°C for 15 min (Eluent: A: H 2 O; B: ACN [0.1%TFA] ) Gradient: 30%B to 50%B in 6 min, 50%B to 80%B in 12 min, 80%B to 30%B in 13 min, 30%B in 15 min. (Detection wavelength at 400 nm) . Commercially obtained PPIX (Sigma-Aldrich, St. Louis, MO, USA) was used as the standard. The peak of PPIX was identified and the peak area in the calibration standards and samples was recorded. The peak area of calibration standards was plotted against the PPIX concentration of working standards. Thus, the relative amount of PPIX was obtained using the calibration curve and associated equation.
  • Proteins were separated by Yarra 3 ⁇ m, SEC-2000, 7.8 ⁇ 300 mm Column at 0.50 ml/min at 25°C for 20 min (Mobile phase: 0.75 M Magnesium Chloride, 0.2 M Tris, 116 ⁇ M EDTA) . (Detection wavelength at 410 nm) .
  • p50 value was determined by HEMOX-analyzer. 1.5 mg of purified protein were diluted in 3.5 ml of buffer (HEPES 100 mM, KCl 100 mM, pH7.3) with or without 2, 3-DPG (4 mM) . The sample buffer is drawn into a cuvette and the temperature of the mixture is equilibrated and brought to 37°C; the sample is then oxygenated to 100%with air. After adjustment of the pO 2 value, the sample is deoxygenated with nitrogen. During the deoxygenation process, the curve is recorded. The p50 value is extrapolated on the x-axis as the point at which O 2 saturation is 50%.
  • Liver tissue oxygenation was directly monitored by the in vivo monitoring system (Oxford Optronix, UK) during the ischemia and reperfusion procedures in Buffalo rats. Briefly, a largearea-surface (LAS) oxygen sensor (Oxford Optronix, UK) was placed between the right hepatic lobe and triangle lobe of the rat livers. The branch of hepatic artery and portal vein to right and triangle lobes were clamped. YQ (bovine fumaryl cross-linked hemoglobin –positive control group) (0.2 g/kg) , TBM1/TBM9 (0.2 g/kg) , or ringer’s acetate buffer (control group) were administered intravenously. Liver oxygen tension was continuously measured during hepatic ischemia reperfusion injury: (1) baseline; (2) after infusion of YQ, TBM1/TBM9, or ringer’s acetate buffer.
  • LAS largearea-surface oxygen sensor
  • Recombinant hemoglobins were diluted to 1 mg/ml with 0.1 M sodium phosphate plus 1 mM EDTA at pH 7.0 at room temperature.
  • Sample solution was oxygenated with compressed air by Hemox Analyzer (TCS scientific) for 20 min at room temperature. Azide-induced oxidation was started by adding 55.6 ⁇ l of 2 M sodium azide to 1 ml of oxygenated sample solution. The sample solution was then transferred without delay into cuvettes, sealing with parafilm to prevent evaporation. Visible spectra from 400 nm to 800 nm were recorded by Multiskan GO with AuDROP plate (thermos scientific) under room temperature in fast mode at 0, 1, 2, 3, 4, 5, 6, 24 and 48 h. Readings at 578 nm, 630 nm, and 700 nm were used to calculate the concentration of oxy-Hb with the equation below:
  • the initial rate of oxidation was calculated by an exponential fitting of the first 6 h of data.
  • Tumor volume was calculated according to the following standard formula: (the longest diameter) ⁇ 0.5 ⁇ (the shortest diameter) 2 .
  • the tumor volume was monitored twice per week.
  • FIG. 12A tumors grew rapidly in mice treated with PBS (control group) in about 14 days after the treatment. Tumor growth was slowed down significantly in mice in TBM1 group compared with control groups (p ⁇ 0.05) .
  • FIG. 12B showed tumor volume after 14 days treatments of TBM1.
  • tumor reached a volume of 800 mm 3 which was substantially higher than that of the TBM1 treatment group (377 mm 3 ) .
  • mice were anesthetized by intraperitoneal injection of xylazine (20 mg/kg) and ketamine (100 mg/kg) .
  • the left femoral artery was excised and ligated from its proximal origin as a branch of the external iliac artery to the distal point where it bifurcates into the saphenous and popliteal arteries.
  • Tissue perfusion of the hind limbs were assessed serially at baseline, immediate after femoral artery ligation, and on Day 7 after administration of the allocated treatments by using laser Doppler imaging system (Moor instruments, Devon, UK) . Mice were anesthetized during the measurement procedure. The digital color-coded images were captured and analyzed to quantify blood flow in the region from the knee joint to the toes.
  • single intravenous TBM1 injection at 800 mg/kg results in an improvement of tissue perfusion in a murine model of critical limb ischemia.
  • TBM1 100, 200 mg/kg or PBS as a control mice
  • mice As shown in the FIG. 14, no significant differences in weights were seen between the TBM1 treatment groups and control group (both for Balb/C mice and ICR mice) .
  • jugular catheter was surgically implanted into the right jugular vein of the rats at least 4 days before the dosing day.
  • animals were weighted and assigned into 6 per groups with half numbers of male and female.
  • TBM1 was drawn into syringe and connected to an extension tube with a 0.22 um filter for injection. The infusion was given at a constant rate by motorized syringe pump.
  • the rats were sacrificed and the hearts were harvested, fixed in formalin and processed for histological evaluation (H&E staining) . There was no evidence of drug induced cardiomyopathy in total six rats.
  • the present disclosure provides recombinant hemoglobins useful for treating oxygen deficiency related diseases or conditions, such as cancer, stroke, hemorrhagic shock, acute mountain sickness (AMS) , peripheral arterial disease (PAD) and Parkinson’s disease (PD) .
  • the recombinant hemoglobins described herein can have increased oxygen carrying capacity.
  • the therapeutic use of the pharmaceutical compositions comprising the recombinant hemoglobins described herein can require a reduced clinical dosage, which increases the safety of such therapeutic use in a subject in need thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)

Abstract

L'invention concerne des hémoglobines recombinantes ayant une capacité de transport d'oxygène améliorée et des procédés de préparation et d'utilisation de celles-ci. L'invention concerne également une composition pharmaceutique comprenant l'hémoglobine recombinante utile pour traiter des maladies ou des états liés à une déficience en oxygène, tels qu'un accident vasculaire cérébral, un choc hémorragique, une maladie artérielle périphérique (PAD), le mal de montagne aigu (AMS), le cancer et la maladie de Parkinson (PD).
EP20747899.1A 2019-02-01 2020-02-03 Hémoglobines recombinantes et leurs procédés de préparation et d'utilisation Withdrawn EP3837280A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799829P 2019-02-01 2019-02-01
PCT/CN2020/074173 WO2020156556A1 (fr) 2019-02-01 2020-02-03 Hémoglobines recombinantes et leurs procédés de préparation et d'utilisation

Publications (2)

Publication Number Publication Date
EP3837280A1 true EP3837280A1 (fr) 2021-06-23
EP3837280A4 EP3837280A4 (fr) 2022-05-18

Family

ID=71837799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20747899.1A Withdrawn EP3837280A4 (fr) 2019-02-01 2020-02-03 Hémoglobines recombinantes et leurs procédés de préparation et d'utilisation

Country Status (9)

Country Link
US (1) US10752672B1 (fr)
EP (1) EP3837280A4 (fr)
JP (1) JP7066067B2 (fr)
KR (1) KR102436043B1 (fr)
CN (1) CN113166230A (fr)
AU (1) AU2020214952B2 (fr)
CA (1) CA3113147C (fr)
NZ (1) NZ774144A (fr)
WO (1) WO2020156556A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021110127A1 (fr) * 2019-12-06 2021-06-10 Cheer Global Limited Méthode de traitement d'une maladie intestinale inflammatoire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5599907A (en) * 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
ATE246246T1 (de) * 1989-05-10 2003-08-15 Baxter Biotech Tech Sarl Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
WO1998050430A2 (fr) 1997-05-02 1998-11-12 Somatogen, Inc. Mutants d'hemoglobine avec expression soluble accrue et/ou evacuation reduite d'oxyde nitrique
EP1950298A3 (fr) * 1997-05-02 2008-12-24 Baxter Biotech Technology S.A.R.L. Mutants d'hémoglobine dotés d'une expression soluble accrue et/ou d'une évacuation réduite de l'oxyde nitrique
AU784195B2 (en) 1999-11-12 2006-02-16 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
WO2019003155A1 (fr) * 2017-06-27 2019-01-03 Vision Global Holdings Limited Compositions pour thérapie photodynamique et diagnostic par fluorescence de cancers et d'autres maladies

Also Published As

Publication number Publication date
WO2020156556A1 (fr) 2020-08-06
CN113166230A (zh) 2021-07-23
KR20210130712A (ko) 2021-11-01
JP7066067B2 (ja) 2022-05-12
US10752672B1 (en) 2020-08-25
JP2022515560A (ja) 2022-02-18
EP3837280A4 (fr) 2022-05-18
CA3113147C (fr) 2022-03-08
AU2020214952A1 (en) 2021-08-19
KR102436043B1 (ko) 2022-08-23
US20200247877A1 (en) 2020-08-06
AU2020214952B2 (en) 2022-03-03
NZ774144A (en) 2022-02-25
CA3113147A1 (fr) 2020-08-06

Similar Documents

Publication Publication Date Title
JP2007181465A (ja) マクロファージ炎症蛋白変種をコードするポリヌクレオチド
JPH05255392A (ja) Ａ−ｃ−ｂプロインスリン、その製造法および使用法、およびインスリン生産の中間体
AU2015283394B2 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US20160213760A1 (en) Aprotinin-derived polypeptide-antibody conjugates
KR102304114B1 (ko) Ny-eso에 대한 고친화력 tcr
US20200062811A1 (en) Yap protein inhibiting polypeptide and application thereof
EP4159758A1 (fr) Protéine de fusion rhfgf21, polynucléotide codant pour la protéine de fusion rhfgf21, composition contenant la protéine de fusion rhfgf21, et utilisation de la protéine de fusion rhfgf21
US10441628B2 (en) High activity tumour inhibitor and preparation method and use thereof
JPH0229317B2 (fr)
AU2020214952B2 (en) Recombinant hemoglobins and methods of preparation and use thereof
EP0362259A1 (fr) Procede de production de cystatine c ou modifications de la cystatine et sequence d'adn destinee a etre utilisee lors de la realisation dudit procede.
KR20210108941A (ko) Afp 항원 인식을 위한 고친화력 t 세포 수용체
CN105884876B (zh) 一种蚯蚓多肽、其编码序列及其应用
CN107987144B (zh) 一种蜈蚣多肽SLP_SsTx及其编码基因和应用
CN113501862A (zh) 一种多肽及其在制备免疫调节药物中的应用
JPS60260522A (ja) 遺伝子組換体が生産する生理活性物質の安定化法
CN113773400B (zh) 一种门冬胰岛素衍生物及其应用
CN113773391B (zh) 一种门冬胰岛素的制备方法
WO2024037263A1 (fr) Peptide synthétique ayant une faible toxicité in vivo pour inhiber la génération de toxines de staphylococcus aureus et son utilisation
KR20210047143A (ko) 위치특이적으로 비천연아미노산이 도입된 요산산화효소 생산방법, 그의 알부민 복합체 생산 공정 및 그의 약학조성물
WO1995009871A1 (fr) Nouveau peptide antitumoral
JPH03133381A (ja) 血小板ファクター４の発現ベクター、血小板ファクター４融合蛋白、形質転換微生物及び血小板ファクター４の製造法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220419

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/08 20060101ALI20220411BHEP

Ipc: A61K 38/42 20060101ALI20220411BHEP

Ipc: C07K 14/805 20060101AFI20220411BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240229